Study to Evaluate Safety and Immunogenicity of a Prime-Boost Regimen of rVSV-Nipah Virus Vaccine Candidate PHV02 in Healthy Adult Subjects

Inclusion Criteria: * Healthy, adult, male or non-pregnant, non-lactating females * Given written informed consent * No clinically significant health problems * Negative test for SARS-CoV-2 * Agree to avoid conception through Day 57 * Agree to minimize blood and body fluid exposures to others after vaccination through Day 57 * Agree to avoid exposure to immunocompromised persons after vaccination through Day 57 * Agree to avoid employment in industry involved with livestock after vaccination through Day 57 Exclusion Criteria: * Prior infection with Nipah virus, related Henipaviruses or Ebola virus * Prior infection with vesicular stomatitis virus (VSV) * Received VSV-vectored vaccine or Ebola vaccine * BMI \< 18.5 or ≥ 35 * Healthcare worker with direct physical contact with patients * Childcare worker in direct contact with children 5 years old or younger * Household contact who is immunodeficient, or on immunosuppressive medication * Hands-on food preparation job * Primary care or treatment of cattle, horses, or swine * Hepatitis B, hepatitis C, HIV-1, HIV-2, diabetes, atopic dermatitis (eczema), chronic inflammatory disease, autoimmune or autoinflammatory disorder, malignancy, chronic or active neurologic disorder * History of severe reactions to any vaccine or history of severe allergies * Receipt of investigational product up to 30 days prior to, or planned receipt within 196 days after randomization, or ongoing participation in another interventional clinical trial. * Receipt of licensed non-live vaccines within 14 days of planned study immunization (30 days for live vaccines) or planned receipt of non-live or live vaccine within 60 days after first study immunization (30 days after the 2nd vaccination). * Known allergy to components of PHV02 * Injection sites obscured by tattoos or physical condition * Significant psychiatric or medical condition or laboratory abnormality on screening * History of Guillain Barre Syndrome or any chronic or acute neurological disorder * Alcohol or illicit drug abuse within past 5 years * Pregnant or lactating female * Administration of blood or IgG within 120 days preceding study * History of blood donation within 60 days of study * Unwilling to undergo diagnostic evaluation of rash (skin biopsy, if indicated) or joint symptoms (arthrocentesis if indicated by joint effusion), in both cases if acceptable to subject * Elective surgery planned during the study period